Literature DB >> 21173534

Malignant mesothelioma: a clinical study of 238 cases.

Steven E Haber1, Jason M Haber.   

Abstract

Malignant mesothelioma is a diffuse tumor arising in the pleura, peritoneum, or other serosal surface and is closely associated with asbestos exposure. An estimated 2,500 to 3,000 cases are diagnosed each year in the United States. Although there are individual case reports and small series detailing the clinical aspects of mesothelioma, few studies examine a large series of patients with malignant mesothelioma from the clinical perspective. This study reports on the findings of 238 cases of malignant mesothelioma from a private consultative medical practice. Most cases had a history of occupational asbestos exposure. The mean latency was 48.5 yr, with women having a longer latency than men. The mean age at diagnosis was 70. Survival overall was poor (mean 8.8 months), but treatment was beneficial (mean 11.3 versus 6.4 months). Epithelioid histology conferred a survival advantage over sarcomatoid and responded better to treatment. Our data support an inverse relationship between asbestos dose and latency.

Entities:  

Mesh:

Year:  2010        PMID: 21173534     DOI: 10.2486/indhealth.ms1147

Source DB:  PubMed          Journal:  Ind Health        ISSN: 0019-8366            Impact factor:   2.179


  14 in total

1.  Adjuvant intensity-modulated proton therapy in malignant pleural mesothelioma. A comparison with intensity-modulated radiotherapy and a spot size variation assessment.

Authors:  S Lorentini; M Amichetti; L Spiazzi; S Tonoli; S M Magrini; F Fellin; M Schwarz
Journal:  Strahlenther Onkol       Date:  2012-02-10       Impact factor: 3.621

2.  Mesothelioma in Mongolia: case report.

Authors:  Naransukh Damiran; Khishigtogtokh Davaajav; Erdenechimeg Erdenebayar; Burmaa Gomboloi; Arthur L Frank
Journal:  Int J Occup Environ Health       Date:  2015-01-13

3.  Pleural and peritoneal mesotheliomas in the Friuli Venezia Giulia register: data analysis from 1995 to 2015 in Northeastern Italy.

Authors:  Flavia D'Agostin; Paola De Michieli; Carolin Chermaz; Corrado Negro
Journal:  J Thorac Dis       Date:  2017-04       Impact factor: 2.895

Review 4.  Recent Scientific Evidence Regarding Asbestos Use and Health Consequences of Asbestos Exposure.

Authors:  Manuela Valenzuela; Margarita Giraldo; Sonia Gallo-Murcia; Juliana Pineda; Laura Santos; Juan Pablo Ramos-Bonilla
Journal:  Curr Environ Health Rep       Date:  2016-12

5.  Adaptation of a chemosensitivity assay to accurately assess pemetrexed in ex vivo cultures of lung cancer.

Authors:  Sarah L Suchy; Rodney J Landreneau; Matthew J Schuchert; Dakun Wang; Paul R Ervin; Stacey L Brower
Journal:  Cancer Biol Ther       Date:  2012-10-31       Impact factor: 4.742

6.  Changing pattern in malignant mesothelioma survival.

Authors:  Jennifer Faig; Suzanne Howard; Edward A Levine; Gary Casselman; Mary Hesdorffer; Jill A Ohar
Journal:  Transl Oncol       Date:  2015-02       Impact factor: 4.243

7.  Malignant peritoneal mesothelioma with lymph node metastasis that originated in the transverse colon.

Authors:  Yusuke Takehara; Shungo Endo; Yuichi Mori; Kenta Nakahara; Daisuke Takayanagi; Shoji Shimada; Tomokatsu Omoto; Chiyo Maeda; Shumpei Mukai; Eiji Hidaka; Fumio Ishida; Jun-ichi Tanaka; Shin-ei Kudo
Journal:  World J Surg Oncol       Date:  2014-04-23       Impact factor: 2.754

Review 8.  Perspectives on refractory ceramic fiber (RCF) carcinogenicity: comparisons with other fibers.

Authors:  Helmut Greim; Mark J Utell; L Daniel Maxim; Ron Niebo
Journal:  Inhal Toxicol       Date:  2014-09-29       Impact factor: 2.724

9.  Malignant peritoneal mesothelioma: correlation between CT imaging features and histologic subtypes.

Authors:  Isha D Atre; Gaurav V Watane; Mukesh G Harisinghani
Journal:  Abdom Radiol (NY)       Date:  2021-08-03

10.  The latency period of mesothelioma among a cohort of British asbestos workers (1978-2005).

Authors:  G Frost
Journal:  Br J Cancer       Date:  2013-08-29       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.